<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:10pt Arial, sans-serif; }
 .font2 { font:11pt Arial, sans-serif; }
 .font3 { font:18pt Arial, sans-serif; }
 .font4 { font:10pt Times New Roman, serif; }
 .font5 { font:13pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font5">J.P. Morgan</span></p>
<p><span class="font0" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font0" style="font-weight:bold;">19 May 2016</span></p>
<p><span class="font0" style="font-weight:bold;">Michelle Wei, CFA</span></p>
<p><span class="font0" style="font-weight:bold;">(852) 2800-8562</span></p>
<p><a href="mailto:michelle.z.wei@jpmorgan.com"><span class="font0" style="font-weight:bold;">michelle.z.wei@jpmorgan.com</span></a></p>
<div>
<p><span class="font0" style="font-weight:bold;">20</span></p>
</div><br clear="all">
<div>
<p><a name="bookmark0"></a><span class="font3"><a name="bookmark1"></a>Investment Thesis, Valuation and Risks</span></p>
<p><span class="font2" style="font-weight:bold;">IMAX China Holding Inc </span><span class="font1" style="font-style:italic;">(Overweight Price Target: HK$52.00)</span></p>
<p><span class="font0" style="font-weight:bold;">Investment Thesis</span></p>
<p><span class="font4">IMAX China, the exclusive IMAX theatre system provider to film exhibitors, licensee of the IMAX brand and the sole commercial platform for the release of IMAX format films in Greater China. It is a direct beneficiary of the fast-growing box office and aggressive theatre rollout in China, by taking an asset-light model and without any exposure to the rising content production costs.</span></p>
<p><span class="font0" style="font-weight:bold;">Valuation</span></p>
<p><span class="font4">We adopt DCF valuation methodology to derive the company’s fair value. Our WACC assumption is 10.5%, based on a market risk premium of 7.0%, a risk-free rate of 4.0%, beta of 1.05 and terminal growth rate of 2%. Our DCF-based Dec-17 PT of IMAX China stands at HK$52, implying 22% share price upside.</span></p>
<p><span class="font0" style="font-weight:bold;">Risks to Rating and Price Target</span></p>
<p><span class="font4">Upside risks include: 1) IMAX film's box office beats expectation. 2) Demand for IMAX screens beats expectation. 3) More than expected Chinese language IMAX films. Downside risks include: 1) Dolby gains stronger than expected customer traction and affects demand for IMAX. 2) IMAX films' box office misses expectation. 3) Revenue share of box office with Wanda Cinema Line gets significantly cut in the new contract.</span></p>
</div><br clear="all">
<div>
<p><a name="bookmark2"></a><span class="font3"><a name="bookmark3"></a>This document is being provided for the exclusive use of </span><a href="mailto:res@ubssdic.com"><span class="font3">res@ubssdic.com</span></a><span class="font3">.</span></p>
</div><br clear="all">
</body>
</html>